|
1
|
Islam MS, Protic O, Giannubilo SR, Toti P,
Tranquilli AL, Petraglia F, Castellucci M and Ciarmela P: Uterine
leiomyoma: Available medical treatments and new possible
therapeutic options. J Clin Endocrinol Metab. 98:921–934. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mehine M, Kaasinen E, Mäkinen N, Katainen
R, Kämpjärvi K, Pitkänen E, Heinonen HR, Bützow R, Kilpivaara O,
Kuosmanen A, et al: Characterization of uterine leiomyomas by
whole-genome sequencing. N Engl J Med. 369:43–53. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Eltoukhi HM, Modi MN, Weston M, Armstrong
AY and Stewart EA: The health disparities of uterine fibroid tumors
for African American women: A public health issue. Am J Obstet
Gynecol. 210:194–199. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Drayer SM and Catherino WH: Prevalence,
morbidity, and current medical management of uterine leiomyomas.
Int J Gynaecol Obstet. 131:117–122. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bosetti C, Rosato V, Gallus S, Cuzick J
and La Vecchia C: Aspirin and cancer risk: A quantitative review to
2011. Ann Oncol. 23:1403–1415. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rothwell PM, Price JF, Fowkes FG,
Zanchetti A, Roncaglioni MC, Tognoni G, Lee R, Belch JF, Wilson M,
Mehta Z, et al: Short-term effects of daily aspirin on cancer
incidence, mortality, and non-vascular death: Analysis of the time
course of risks and benefits in 51 randomised controlled trials.
Lancet. 379:1602–1612. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Thun MJ, Jacobs EJ and Patrono C: The role
of aspirin in cancer prevention. Nat Rev Clin Oncol. 9:259–267.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Drew DA, Cao Y and Chan AT: Aspirin and
colorectal cancer: The promise of precision chemoprevention. Nat
Rev Cancer. 16:173–186. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Johnson CC, Hayes RB, Schoen RE, Gunter
MJ, Huang WY and Team PT: PLCO Trial Team: Non-steroidal
anti-inflammatory drug use and colorectal polyps in the Prostate,
Lung, Colorectal, And Ovarian Cancer Screening Trial. Am J
Gastroenterol. 105:2646–2655. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gamba CA, Swetter SM, Stefanick ML, Kubo
J, Desai M, Spaunhurst KM, Sinha AA, Asgari MM, Sturgeon S and Tang
JY: Aspirin is associated with lower melanoma risk among
postmenopausal Caucasian women: The Women's Health Initiative.
Cancer. 119:1562–1569. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Veitonmäki T, Tammela TL, Auvinen A and
Murtola TJ: Use of aspirin, but not other non-steroidal
anti-inflammatory drugs is associated with decreased prostate
cancer risk at the population level. Eur J Cancer. 49:938–945.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rothwell PM, Wilson M, Price JF, Belch JF,
Meade TW and Mehta Z: Effect of daily aspirin on risk of cancer
metastasis: A study of incident cancers during randomised
controlled trials. Lancet. 379:1591–1601. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
MacDonald BT, Tamai K and He X:
Wnt/beta-catenin signaling: Components, mechanisms, and diseases.
Dev Cell. 17:9–26. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Park IS, Jo JR, Hong H, Nam KY, Kim JB,
Hwang SH, Choi MS, Ryu NH, Jang HJ, Lee SH, et al: Aspirin induces
apoptosis in YD-8 human oral squamous carcinoma cells through
activation of caspases, down-regulation of Mcl-1, and inactivation
of ERK-1/2 and AKT. Toxicol In Vitro. 24:713–720. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang D and Dubois RN: The role of COX-2 in
intestinal inflammation and colorectal cancer. Oncogene.
29:781–788. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ding JH, Yuan LY, Huang RB and Chen GA:
Aspirin inhibits proliferation and induces apoptosis of multiple
myeloma cells through regulation of Bcl-2 and Bax and suppression
of VEGF. Eur J Haematol. 93:329–339. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Niault TS and Baccarini M: Targets of Raf
in tumorigenesis. Carcinogenesis. 31:1165–1174. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hong W, Abi-Raad R, Alomari AK, Hui P and
Buza N: Diagnostic application of KRAS mutation testing in uterine
microglandular proliferations. Hum Pathol. 46:1000–1005. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lim KH and Counter CM: Reduction in the
requirement of oncogenic Ras signaling to activation of PI3K/AKT
pathway during tumor maintenance. Cancer Cell. 8:381–392. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Schubbert S, Bollag G, Lyubynska N, Nguyen
H, Kratz CP, Zenker M, Niemeyer CM, Molven A and Shannon K:
Biochemical and functional characterization of germ line KRAS
mutations. Mol Cell Biol. 27:7765–7770. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shieh A, Ward AF, Donlan KL,
Harding-Theobald ER, Xu J, Mullighan CG, Zhang C, Chen SC, Su X,
Downing JR, et al: Defective K-Ras oncoproteins overcome impaired
effector activation to initiate leukemia in vivo. Blood.
121:4884–4893. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Castellano E, Sheridan C, Thin MZ, Nye E,
Spencer-Dene B, Diefenbacher ME, Moore C, Kumar MS, Murillo MM,
Grönroos E, et al: Requirement for interaction of PI3-kinase p110α
with RAS in lung tumor maintenance. Cancer Cell. 24:617–630. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Murillo MM, Zelenay S, Nye E, Castellano
E, Lassailly F, Stamp G and Downward J: RAS interaction with PI3K
p110α is required for tumor-induced angiogenesis. J Clin Invest.
124:3601–3611. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
di Magliano MP and Logsdon CD: Roles for
KRAS in pancreatic tumor development and progression.
Gastroenterology. 144:1220–1229. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liao X, Lochhead P, Nishihara R, Morikawa
T, Kuchiba A, Yamauchi M, Imamura Y, Qian ZR, Baba Y, Shima K, et
al: Aspirin use, tumor PIK3CA mutation, and colorectal-cancer
survival. N Engl J Med. 367:1596–1606. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Turturro SB, Najor MS, Ruby CE, Cobleigh
MA and Abukhdeir AM: Mutations in PIK3CA sensitize breast cancer
cells to physiologic levels of aspirin. Breast Cancer Res Treat.
156:33–43. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Di X, Yu L, Moore AB, Castro L, Zheng X,
Hermon T and Dixon D: A low concentration of genistein induces
estrogen receptor-alpha and insulin-like growth factor-I receptor
interactions and proliferation in uterine leiomyoma cells. Hum
Reprod. 23:1873–1883. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gao X, Yu L, Castro L, Tucker CJ, Moore
AB, Xiao H and Dixon D: An essential role of p27 downregulation in
fenvalerate-induced cell growth in human uterine leiomyoma and
smooth muscle cells. Am J Physiol Endocrinol Metab.
303:E1025–E1035. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hafizi S, Ibraimi F and Dahlbäck B: C1-TEN
is a negative regulator of the Akt/PKB signal transduction pathway
and inhibits cell survival, proliferation, and migration. FASEB J.
19:971–973. 2005.PubMed/NCBI
|
|
30
|
Barber AJ, Nakamura M, Wolpert EB, Reiter
CE, Seigel GM, Antonetti DA and Gardner TW: Insulin rescues retinal
neurons from apoptosis by a phosphatidylinositol
3-kinase/Akt-mediated mechanism that reduces the activation of
caspase-3. J Biol Chem. 276:32814–32821. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Silverstein FE, Faich G, Goldstein JL,
Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM,
Stenson WF, et al: Gastrointestinal toxicity with celecoxib vs
nonsteroidal anti-inflammatory drugs for osteoarthritis and
rheumatoid arthritis: the CLASS study: A randomized controlled
trial. Celecoxib Long-term Arthritis Safety Study. JAMA.
284:1247–1255. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Campbell CL, Smyth S, Montalescot G and
Steinhubl SR: Aspirin dose for the prevention of cardiovascular
disease: A systematic review. JAMA. 297:2018–2024. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Verdoodt F, Friis S, Dehlendorff C,
Albieri V and Kjaer SK: Non-steroidal anti-inflammatory drug use
and risk of endometrial cancer: A systematic review and
meta-analysis of observational studies. Gynecol Oncol. 140:352–358.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pathi S, Jutooru I, Chadalapaka G, Nair V,
Lee SO and Safe S: Aspirin inhibits colon cancer cell and tumor
growth and downregulates specificity protein (Sp) transcription
factors. PLoS One. 7:e482082012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Olivan M, Rigau M, Colás E, Garcia M,
Montes M, Sequeiros T, Regis L, Celma A, Planas J, Placer J, et al:
Simultaneous treatment with statins and aspirin reduces the risk of
prostate cancer detection and tumorigenic properties in prostate
cancer cell lines. BioMed Res Int. 2015:7621782015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Juárez Olguín H, Pérez Flores J, Asseff
Lares I, Abdalá Loredo A and Rodríguez Carbajal L: Comparative
pharmacokinetics of acetyl salicylic acid and its metabolites in
children suffering from autoimmune diseases. Biopharm Drug Dispos.
25:1–7. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cantley LC: The phosphoinositide 3-kinase
pathway. Science. 296:1655–1657. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gupta S, Ramjaun AR, Haiko P, Wang Y,
Warne PH, Nicke B, Nye E, Stamp G, Alitalo K and Downward J:
Binding of ras to phosphoinositide 3-kinase p110alpha is required
for ras-driven tumorigenesis in mice. Cell. 129:957–968. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yang HW, Shin MG, Lee S, Kim JR, Park WS,
Cho KH, Meyer T and Heo WD: Cooperative activation of PI3K by Ras
and Rho family small GTPases. Mol Cell. 47:281–290. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Rao CV, Mohammed A, Janakiram NB, Li Q,
Ritchie RL, Lightfoot S, Vibhudutta A and Steele VE: Inhibition of
pancreatic intraepithelial neoplasia progression to carcinoma by
nitric oxide-releasing aspirin in p48(Cre/+)-LSL-Kras(G12D/+) mice.
Neoplasia. 14:778–787. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Downward J: Targeting RAS signalling
pathways in cancer therapy. Nat Rev Cancer. 3:11–22. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Gelb MH, Brunsveld L, Hrycyna CA,
Michaelis S, Tamanoi F, Van Voorhis WC and Waldmann H: Therapeutic
intervention based on protein prenylation and associated
modifications. Nat Chem Biol. 2:518–528. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zimmermann G, Papke B, Ismail S, Vartak N,
Chandra A, Hoffmann M, Hahn SA, Triola G, Wittinghofer A, Bastiaens
PI, et al: Small molecule inhibition of the KRAS-PDEδ interaction
impairs oncogenic KRAS signalling. Nature. 497:638–642. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Pylayeva-Gupta Y, Grabocka E and Bar-Sagi
D: RAS oncogenes: Weaving a tumorigenic web. Nat Rev Cancer.
11:761–774. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Sunaga N, Shames DS, Girard L, Peyton M,
Larsen JE, Imai H, Soh J, Sato M, Yanagitani N, Kaira K, et al:
Knockdown of oncogenic KRAS in non-small cell lung cancers
suppresses tumor growth and sensitizes tumor cells to targeted
therapy. Mol Cancer Ther. 10:336–346. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Lerner EC, Zhang TT, Knowles DB, Qian Y,
Hamilton AD and Sebti SM: Inhibition of the prenylation of K-Ras,
but not H- or N-Ras, is highly resistant to CAAX peptidomimetics
and requires both a farnesyltransferase and a
geranylgeranyltransferase I inhibitor in human tumor cell lines.
Oncogene. 15:1283–1288. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Los M, Stroh C, Jänicke RU, Engels IH and
Schulze-Osthoff K: Caspases: More than just killers? Trends
Immunol. 22:31–34. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Song R, Mahidhara RS, Zhou Z, Hoffman RA,
Seol DW, Flavell RA, Billiar TR, Otterbein LE and Choi AM: Carbon
monoxide inhibits T lymphocyte proliferation via caspase-dependent
pathway. J Immunol. 172:1220–1226. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Cardone MH, Roy N, Stennicke HR, Salvesen
GS, Franke TF, Stanbridge E, Frisch S and Reed JC: Regulation of
cell death protease caspase-9 by phosphorylation. Science.
282:1318–1321. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Uriarte SM, Joshi-Barve S, Song Z, Sahoo
R, Gobejishvili L, Jala VR, Haribabu B, McClain C and Barve S: Akt
inhibition upregulates FasL, downregulates c-FLIPs and induces
caspase-8-dependent cell death in Jurkat T lymphocytes. Cell Death
Differ. 12:233–242. 2005. View Article : Google Scholar : PubMed/NCBI
|
